MEIP
vs
S&P 500
MEIP
S&P 500
Over the past 12 months, MEIP has outperformed S&P 500, delivering a return of +29% compared to the S&P 500's +14% growth.
Stocks Performance
MEIP vs S&P 500
Performance Gap
MEIP vs S&P 500
Performance By Year
MEIP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MEI Pharma Inc
Glance View
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company went IPO on 2003-12-18. The firm is focused on development and commercialization of novel cancer therapies. The firm's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The firm is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).
